By GLP-1 StudioGLP1Coach
← All tools

Free tool · GLP-1 side effects

Which side effect are you dealing with?

Pick one below, or start typing. You will get a plain explanation of why it can happen on a GLP-1, what generally helps, and when it is time to call your prescriber.

Some symptoms skip this page, get care now

The prescribing information tells patients and clinicians to watch for a few serious conditions. Do not manage these at home:

  • Severe or persistent stomach pain, sometimes spreading to the back, with or without vomiting, a possible sign of pancreatitis.
  • Pain in the upper right belly, fever, or yellowing of the skin or eyes, possible gallbladder disease, which weight loss itself makes more likely.
  • Swelling of the face or throat, trouble breathing or swallowing, severe rash, signs of a serious allergic reaction. This one is 911, not a phone call.
  • Unable to keep any fluids down, dehydration on these medications has caused acute kidney injury.
  • Vision changes, if you have diabetes, report them promptly.

This is education, not medical advice

The incidence numbers here come from the semaglutide (Wegovy) trials; tirzepatide and other GLP-1 medications have broadly similar digestive side effects, but your medication's own patient information is the authority for your prescription. Nothing on this page replaces your prescriber. It is meant to make the conversation with them easier.

Sources

4 references
  1. Wegovy (semaglutide) Prescribing Information: Adverse Reactions and Warnings and Precautions. Novo Nordisk. Current label at DailyMed. Source of every incidence percentage on this page (adult adverse-reactions table) and of the warnings on pancreatitis, gallbladder disease, allergic reactions, dehydration-related kidney injury, and diabetic retinopathy.
  2. Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. The American Journal of Clinical Nutrition. 2025;122(1):344–367. doi:10.1016/j.ajcnut.2025.04.023. A corrigendum was published in 2026. Source of the management guidance: small meals every 3–4 hours, limiting fatty and high-fiber foods early on, fluids between meals, prunes and high-water foods for constipation, fiber supplements and stool softeners, anti-diarrheal options, alcohol worsening nausea and reflux, and nutrient adequacy for hair and energy.
  3. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183. The trial program behind the label's adverse-reaction table; gastrointestinal events were mostly mild-to-moderate and clustered around dose escalation.
  4. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205–216. doi:10.1056/NEJMoa2206038. Tirzepatide's side-effect profile: the same gastrointestinal events led, also mostly mild-to-moderate and during dose escalation.

Coaching

Would it help to talk this through with me?

A guide can explain a side effect. Coaching helps you figure out what to change in your actual week, and how to bring it up with your prescriber.

Work with me →